Clinical Trials Logo

Clinical Trial Summary

The planned randomized clinical trial will longitudinally test a tailored, web-based drug abuse prevention program with a nationwide sample of 15- to 17-year-old sexual minority youth (youth who identify as gay, lesbian, bisexual, or unsure of their sexual orientation).


Clinical Trial Description

The randomized controlled trial will include at least 890 sexual-minority youth from the United States. Study participants will be 15- to 17-year-old youth recruited from Facebook/Instagram. All youth will complete pretest measures online. Intervention-arm youth will then interact with the 9-session program; youth in the control arm will have access to an attention-placebo website. All youth will then complete posttest measures (immediately following intervention completion and estimated to be approximately 5 months after study onset) and 1-, 2-, and 3-year follow-up measures. Across posttest and annual follow-up measurement occasions, data analyses will examine rates of 30-day drug use between study arms. The investigators will also examine intervention effects on mediator variables associated with drug use and assess the extent to which changes in mediator variables explain differences in drug use between arms. Youth assigned to the intervention arm will have access to 9 intervention sessions delivered online. The sessions will be housed on a website with entertainment features youth seek: life hacks, features on LGBTQ leaders, fortunes, horoscopes, inspiring quotes, and health-related resources. To ensure that youths' expectations for study participation are equivalent across arms and to account for the non-active components of the experimental intervention, the investigators designed the attention-placebo arm. Youth assigned to the attention-placebo arm will have access to the website with entertainment features: life hacks, features on LGBTQ leaders, fortunes, horoscopes, inspiring quotes, and health-related resources. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03954535
Study type Interventional
Source Columbia University
Contact
Status Completed
Phase N/A
Start date January 15, 2020
Completion date March 30, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04070521 - EEG Monitoring in the Emergency Department
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Active, not recruiting NCT03129334 - Preventing Prescription Drug Abuse in Middle School Students N/A
Completed NCT02733003 - Implementation Research for Vulnerable Women in South Africa N/A
Completed NCT02573948 - Feasibility of Interventions on People Who Inject Drugs in Vietnam
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Withdrawn NCT01523444 - Advancing Adolescent Screening and Brief Intervention Protocols in Primary Care Settings Phase 3
Withdrawn NCT01847300 - cSBI-M for Young Military Personnel N/A
Completed NCT01481428 - Reducing High Risk Behavior in Treatment Court Phase 1
Completed NCT01601743 - Exercise as a Behavioral Treatment for Cocaine Dependence N/A
Completed NCT01591239 - Home-Based Program to Help Parents of Drug Abusing Adolescents N/A
Active, not recruiting NCT00847548 - Treatment of Intimate Partner Violence and Substance Abuse in a Forensic Setting N/A
Withdrawn NCT01228890 - Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT) Phase 3
Completed NCT01614015 - Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial Phase 2
Completed NCT01621334 - The Men's Domestic Abuse Check-Up Engages Adult Men Concerned About Their Abusive Behavior and Alcohol or Drug Use Phase 1
Completed NCT00841711 - Transitions: Linkages From Jail To Community N/A
Completed NCT00717444 - Healthy Activities for Prize Incentives N/A
Completed NCT01188434 - Integrating Interventions for Maternal Substance Abuse Phase 1
Completed NCT01465490 - Monitoring and Feedback in Substance Abuse Treatment Phase 1/Phase 2
Completed NCT00685074 - Computer-based Brief Intervention for Perinatal Substance Abuse Phase 1/Phase 2